224 related articles for article (PubMed ID: 21815182)
1. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
[No Abstract] [Full Text] [Related]
2. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
3. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
4. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
[No Abstract] [Full Text] [Related]
5. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.
Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP
Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases.
Bael TE; Peterson BL; Gollob JA
Melanoma Res; 2008 Apr; 18(2):147-51. PubMed ID: 18337652
[TBL] [Abstract][Full Text] [Related]
9. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
10. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
[TBL] [Abstract][Full Text] [Related]
11. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
12. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
Ofran Y; Avivi I; Gesundheit B; Or R; Rowe JM; Zuckerman T
Am J Hematol; 2007 Apr; 82(4):332-3. PubMed ID: 17080434
[No Abstract] [Full Text] [Related]
13. Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
Alimoghaddam K; Shariftabrizi A; Tavangar SM; Sanaat Z; Rostami S; Jahani M; Ghavamzadeh A
Leuk Lymphoma; 2006 Jan; 47(1):81-8. PubMed ID: 16321832
[TBL] [Abstract][Full Text] [Related]
14. [Effects of arsenic trioxide on Id4 methylation status in bone marrow mononuclear cells and its clinical efficacy for myelodysplastic syndrome].
Shao X; Lu R; Guan X; Liu J; Zhao J; Shao Z; Zhan Z; Ma J
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):247-50. PubMed ID: 24666496
[No Abstract] [Full Text] [Related]
15. Arsenic trioxide.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(5):237-8. PubMed ID: 11899773
[No Abstract] [Full Text] [Related]
16. Two cases of monocular visual loss during oral arsenic trioxide therapy of acute promyelocytic leukemia.
Au WY; Hon C; Yau K; Lai WW; Fong BM; Tam S; Kwong YL
Am J Hematol; 2009 Oct; 84(10):699. PubMed ID: 19705432
[No Abstract] [Full Text] [Related]
17. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly.
Pinto A; Zagonel V; Attadia V; Bullian PL; Gattei V; Carbone A; Monfardini S; Colombatti A
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():28-32. PubMed ID: 2483349
[No Abstract] [Full Text] [Related]
18. A combination of thalidomide and arsenic trioxide is effective and well tolerated in patients with myelodysplastic syndromes.
Wei W; Zhou F; Zhang Y; Guo L; Shi H; Hou J
Leuk Res; 2012 Jun; 36(6):715-9. PubMed ID: 22277680
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
20. High frequency of varicella zoster virus reactivation associated with the use of arsenic trioxide in patients with acute promyelocytic leukemia.
Yamakura M; Tsuda K; Ugai T; Sugihara H; Nisihida Y; Takeuchi M; Matsue K
Acta Haematol; 2014; 131(2):76-7. PubMed ID: 24081111
[No Abstract] [Full Text] [Related]
[Next] [New Search]